Form: SC 13D/A

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

July 6, 2018

Exhibit 99.1

 

JOINT FILING AGREEMENT

 

Each of the undersigned hereby agrees that this Amendment No. 8 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended.

 

Date: July 6, 2018

 

  Mayne Pharma Ventures Pty Ltd
   
 

/s/ Nick Freeman

Nick Freeman, Company Secretary

 

 

 

Mayne Pharma International Pty Ltd

 

   
 

/s/ Nick Freeman

Nick Freeman, Company Secretary

 

 

 

Mayne Pharma Group Limited

 

   
 

/s/ Nick Freeman

Nick Freeman, Company Secretary